TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shilpa Medicare Limited ( (IN:SHILPAMED) ) has shared an update.
Shilpa Medicare Limited has announced the approval of its Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg by the Central Drugs Standard Control Organization (CDSCO) for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in India. This approval marks a significant milestone as it positions Shilpa Medicare as the first company globally to launch this novel product for NAFLD, addressing a major unmet medical need. The introduction of NorUDCA, which has demonstrated superior efficacy over placebo, underscores Shilpa’s commitment to innovation and accessible healthcare, potentially impacting millions affected by liver disease in India and beyond.
More about Shilpa Medicare Limited
Shilpa Medicare Limited is an integrated pharmaceutical group specializing in niche Oncology and Non-Oncology APIs, Peptides, Polymers, and differentiated finished dosage formulations such as Orally Dispersible Films and Transdermal Patches. The company also provides end-to-end CDMO services to global pharmaceutical partners, supported by four R&D units and seven manufacturing facilities.
Average Trading Volume: 12,980
Technical Sentiment Signal: Buy
Current Market Cap: 80.38B INR
For an in-depth examination of SHILPAMED stock, go to TipRanks’ Overview page.